BMC Pulmonary Medicine (Sep 2024)

Potential for trans-pulmonary tumor markers in the early diagnosis of lung cancer: a case report

  • Ken Monahan,
  • Michael Kammer,
  • Yan Ru Su,
  • Wade Iams,
  • Eric Grogan,
  • Fabien Maldonado

DOI
https://doi.org/10.1186/s12890-024-03288-z
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Background Measurement of tumor markers from peripheral venous blood is an emerging tool to assist in the early diagnosis of lung cancer. Samples from the pulmonary artery and pulmonary artery wedge position (trans-pulmonary samples) are accessible via right-heart catheterization and, by virtue of their proximity to lung tumors, may increase diagnostic yield. Case presentation We report a case of a 64 year-old woman from whom trans-pulmonary samples were obtained and who was diagnosed 16 months later with recurrent metastatic small cell lung cancer. Carcinoembryonic antigen, cytokeratin fragment 21 − 1 (CYFRA), and human epididymis protein 4 (HE4) levels demonstrated increasing concentrations across the pulmonary circulation. These gradients exceeded the assays’ coefficient of variation by several-fold. For CYFRA and HE4, pulmonary artery wedge concentrations exceeded peripheral venous levels by more than 10% and peripheral arterial levels were up to 8% higher than peripheral venous levels. Conclusions Evaluating the feasibility and utility of trans-pulmonary tumor markers for lung cancer diagnosis in a larger cohort should be considered. The addition of a peripheral arterial sample to standard peripheral venous samples may be a more practical alternative.

Keywords